Raphael E Szalat MD, PhD
Assistant Professor, Hematology & Oncology
820 Harrison Ave | (617) 638-7011rszalat@bu.edu
Biography
I received my medical training at the University of Pierre and Marie Curie, in Paris, France. After Internal Medicine residency, I specialized in Immunology and plasma cell disorders including multiple myeloma and monoclonal gammopathies of clinical significance and became a clinical assistant professor in the department of Immuno-Hematology in Saint-Louis hospital, Paris. I next completed a PhD and post-doc in hematology studying genomics in Multiple Myeloma at the Dana-Farber Cancer Institute, Harvard Medical School in collaboration with La Sorbonne University, Paris and a clinical fellowship in Hematology and Oncology at the Boston University Medical Center. I am currently the multiple myeloma program director and the Stem Cell Transplant director at the Boston University Medical Center. My main interests are to develop myeloma clinical trials and to perform basic and translational research on multiple myeloma and other plasma cell disorders including AL amyloidosis and other monoclonal gammopathy of clinical significance.
Education
Medicine, MD, Université Paris-Sorbonne, Paris IV
PhD, Université Paris-Sorbonne, Paris IV
Publications
Muchtar E, Palladini G, Schonland S, Geyer S, Dooley KE, Dispenzieri A, Wisniowski B, Merlini G, Milani P, Hegenbart U, Dittrich T, Kastritis E, Dimopoulos MA, Sanchorawala V, Szalat R, Liedtke M, Gupta M, Landau H, Lentzsch S, Hughes MS, Cibeira MT, Blade J, Kumar SK, Wechalekar A, Gertz MA. Hepatic response criteria in light chain amyloidosis: a multicenter validation study. Haematologica. 2026 Jan 15. PMID: 41537335.
Published on 1/12/2026Fulciniti M, Yao Y, Perini T, Fong Ng J, Schavgoulidze A, Deng S, Cui J, Encinas Mayoral J, Ladisa F, Young RM, Epstein CB, White CM, Ott CJ, Gulla A, Matulis SM, Sperling AS, Morelli E, Boise LH, Binder M, Szalat R, Samur MK, Anderson KC, Munshi NC. ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. Blood Cancer Discov. 2026 Jan 12; 7(1):129-141. PMID: 41104834.
Published on 12/12/2025Ferri GM, Martinez CB, Acevedo J, Bhatt S, Verma KP, Lee J, Abdallah M, Szalat RE, Sloan JM. Exploring the effect of Duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors. Breast Cancer Res Treat. 2025 Dec 12; 215(1):36. PMID: 41385110.
Published on 12/11/2025Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK. Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma. J Clin Oncol. 2026 Feb; 44(4):321-334. PMID: 41380103.
Published on 10/14/2025Holder EX, Szalat R, Palmer JR, Bertrand KA. Neighborhood disadvantage and multiple myeloma incidence in the Black Women's Health Study. Int J Epidemiol. 2025 Oct 14; 54(6). PMID: 41206638.
Published on 9/22/2025Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R. Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis-Related Acquired Factor X Deficiency. Am J Hematol. 2025 Dec; 100(12):2416-2420. PMID: 40981270.
Published on 9/3/2025Ferri GM, Frank A, Li D, Anand P, Abdallah M, Avalone V, Mark Sloan J, Sanchorawala V, Lerner A, Szalat RE, Petrocca F, Edwards CV, Bell BN. When ICAN(S) Becomes ICAN'T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading. Clin Lymphoma Myeloma Leuk. 2026 Jan; 26(1):e77-e82. PMID: 41015712.
Published on 3/20/2025Battaglini J, Henderson J, Sanchorawala V, Szalat R. Teclistamab therapy for refractory type 1 cryoglobulinemia. Haematologica. 2025 Aug 01; 110(8):1891-1893. PMID: 40109179.
Published on 12/10/2024Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938. PMID: 39348709.
Published on 10/1/2024Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis. JAMA Oncol. 2024 Oct 01; 10(10):1362-1369. PMID: 39088206.